This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwartz, A. G. Articles by Brooks, S. Search for Related Content PubMed PubMed Citation Articles by Schwartz, A. G. Articles by Brooks, S.

Nuclear Estrogen Receptor ß in Lung Cancer: Expression and Survival Differences by Sex

Authors' Affiliations: ¹ Population Studies and Prevention Program, and ² Breast Cancer Program, Karmanos Cancer Institute and Departments of ³ Internal Medicine, ⁴ Pathology, ⁵ Surgery; and ⁶ Biochemistry, Wayne State University School of Medicine, Detroit, Michigan

Requests for reprints: Ann G. Schwartz, Karmanos Cancer Institute, Wayne State University School of Medicine, 110 East Warren Avenue, Detroit, MI 48201. Phone: 313-833-0715; Fax: 313-831-7806; E-mail: schwarta{at}med.wayne.edu.

Purpose: A role for estrogens in determining lung cancer risk and prognosis is suggested by reported sex differences in susceptibility and survival. Archival lung tissue was evaluated for the presence of nuclear estrogen receptor (ER)- and ER-ß and the relationship between ER status, subject characteristics, and survival.

Experimental Design: Paraffin-embedded lung tumor samples were obtained from 214 women and 64 men from two population-based, case-control studies as were 10 normal lung autopsy samples from patients without cancer. Nuclear ER- and ER-ß expression was determined by immunohistochemistry. Logistic regression was used to identify factors associated with ER positivity and Cox proportional hazards models were used to measure survival differences by ER status.

Results: Neither tumor (0 of 94) nor normal (0 of 10) lung tissue stained positive for ER-. Nuclear ER-ß positivity was present in 61% of tumor tissue samples (170 of 278; 70.3% in men and 58.3% in women) and 20% of normal tissue samples (2 of 10; P = 0.01). In multivariate analyses, females were 46% less likely to have ER-ß–positive tumors than males (odds ratio, 0.54; 95% confidence interval, 0.27-1.08). This relationship was stronger and statistically significant in adenocarcinomas (odds ratio, 0.40; 95% confidence interval, 0.18-0.89). Women with ER-ß–positive tumors had a nonsignificant 73% (P = 0.1) increase in mortality, whereas men with ER-ß–positive tumors had a significant 55% (P = 0.04) reduction in mortality compared with those with ER-ß–negative tumors.

Conclusions: This study suggests differential expression by sex and influence on survival in men of nuclear ER-ß in lung cancer, particularly in adenocarcinomas.

This article has been cited by other articles:

				A. G. Schwartz, A. S. Wenzlaff, G. M. Prysak, V. Murphy, M. L. Cote, S. C. Brooks, D. F. Skafar, and F. Lonardo Reproductive Factors, Hormone Use, Estrogen Receptor Expression and Risk of Non Small-Cell Lung Cancer in Women J. Clin. Oncol., December 20, 2007; 25(36): 5785 - 5792. [Abstract] [Full Text] [PDF]

				M. Tsuchiya, M. Iwasaki, T. Otani, J.-i. Nitadori, K. Goto, Y. Nishiwaki, Y. Uchitomi, and S. Tsugane Breast Cancer in First-degree Relatives and Risk of Lung Cancer: Assessment of the Existence of Gene-Sex Interactions Jpn. J. Clin. Oncol., June 23, 2007; (2007) hym048v1. [Abstract] [Full Text] [PDF]